Breath Analysis by Ion Mobility Spectrometry

This study is currently recruiting participants.

Verified May 2011 by Lung Clinic Hemer

Sponsor:

Information provided by:

Lung Clinic Hemer

ClinicalTrials.gov Identifier:

NCT00632307

First received: February 29, 2008

Last updated: June 22, 2011

Last verified: May 2011

History of Changes

Tracking Information

First Received Date ^ICMJE

February 29, 2008

Last Updated Date

June 22, 2011

Start Date ^ICMJE

July 2006

Estimated Primary Completion Date

May 2014 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00632307 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Breath Analysis by Ion Mobility Spectrometry

Official Title ^ICMJE

Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry

Brief Summary

Recognition of disease specific clusters of volatile organic compounds in patients with different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases of interest are:

COPD
tumors
airway infection
interstitial lung disease
sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate pulmonary disorders.

Detailed Description

Recruitment of patients with different lung diseases goes on. First sub-group analysis of patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of VOC-clusters for further validation in a bigger population of patients.

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Time Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Retention: Samples Without DNA

Description:

breath, pleural fluid (only in patients with therapeutic pleurocentesis)

Sampling Method

Non-Probability Sample

Study Population

patients of the lung clinic hemer

Condition ^ICMJE

Lung Diseases

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

1
COPD
2
lung cancer
3
airway infection
4
interstitial lung disease
5
sleep apnea
6
pulmonary disorders with pleural infusions
7
sarcoidosis
8
healthy persons

Publications *

Bunkowski A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbach JI. MCC/IMS signals in human breath related to sarcoidosis-results of a feasibility study using an automated peak finding procedure. J Breath Res. 2009 Dec;3(4):046001. Epub 2009 Sep 23.
Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax. 2009 Sep;64(9):744-8. Epub 2009 Jan 21.
Westhoff M, Litterst P, Freitag L, Baumbach JI. Ion mobility spectrometry in the diagnosis of sarcoidosis: results of a feasibility study. J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):739-51.
Bunkowski,A, Bödeker B, Bader S, Westhoff M, Litterst P, Baumbauch JI.Signals in human breath related to Sarcoidosis. — Results of a feasibility study using MCC/IMS. Int. J. Ion Mobil. Spec. (2009) 12:73-79

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Estimated Enrollment ^ICMJE

1000

Estimated Completion Date

June 2015

Estimated Primary Completion Date

May 2014 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Any patient
Ages 18-90 years old

Gender

Both

Ages

18 Years to 90 Years

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact: Michael Westhoff, MD	004923729082203	michael.westhoff@lkhemer.de
Contact: Patric Litterst, MD	004923729082545	pneumologie@lkhemer.de

Location Countries ^ICMJE

Germany

Administrative Information

NCT Number ^ICMJE

NCT00632307

Other Study ID Numbers ^ICMJE

lkhemer1-2008

Has Data Monitoring Committee

Responsible Party

Michael Westhoff MD, Lung Clinic Hemer

Study Sponsor ^ICMJE

Lung Clinic Hemer

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Michael Westhoff, MD

Lung Clinic Hemer, 58675 Hemer, Germany

Information Provided By

Lung Clinic Hemer

Verification Date

May 2011

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top